Tech Company Financing Transactions
Optimeos Life Sciences Funding Round
Optimeos Life Sciences closed a funding round on 6/25/2026. Investors included Hatch Biofund.
Transaction Overview
Company Name
Announced On
6/25/2026
Transaction Type
Venture Equity
Amount
Unknown
Round
Undisclosed
Investors
Proceeds Purpose
The company intends to use the funds to expand operations and its development efforts.
Company Information
Company Status
Private & Independent
Industry
Life Sciences
Mailing Address
174 Nassau Street 334
Princeton, NJ 08542
USA
Princeton, NJ 08542
USA
Phone
Website
Email Address
Overview
Optimeos is developing a solution suite to overcome crucial formulation challenges and address unmet medical needs. Optimeos' formulation platform navigates diverse obstacles in complex biologics delivery, ranging from the short half-lives of peptide therapeutics to the poor cell specificity of non-viral gene therapies. Next generation nanoparticles advancing in vivo cell and gene therapies: beyond viral & LNP delivery.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Shahram Hejazi
Chief Marketing Officer
Gregory Harriman
Chief Scientific Officer
Chet Markwalter
Chief Technical Officer
Bob Prud'homme
VP - Bus. Development
Jason Smith
VP - R & D
Rob Pagels
Browse more venture capital transactions:
Prev: 6/25/2026: Validar venture capital transaction
Next: 6/25/2026: Float Financial venture capital transaction
Share this article
News on VC Transactions
We do our best to document funding rounds that are announced publicly. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs